Fig. 5

Treatment of mice with either mα-IL-4Rα or rIL-13Rα2 abrogates Th2 response and alters the pattern of macrophage activation despite the presence of IL-25. A Expression of cytokine mRNA in the intestinal tissue IL-25-treated-mice that were also treated with monoclonal anti-mouse IL-4Rα (mα-IL-4Rα) or recombinant IL-13Rα2 (rIL-13Rα2) at 2 weeks post-primary infection (wppi) with E. caproni; B Pattern of macrophage activation analyzed by the expression of marker mRNA of both classical (ArgII and iNOS) and alternative (ArgI and Ym-1) macrophage activation in the intestinal tissue of IL-25-treated-mice that were also treated with mα-IL-4Rα or rIL-13Rα2 at 2 wppi with E. caproni. The RQ of cytokine genes are shown after normalization with β-actin and standardization of the relative amount against the day 0 sample. Vertical bars represent the SD. Lowercase letters (a, b) above bars indicate either significant differences with respect to naïve mice controls (a) or significant differences between groups (b), at p  < 0.05